Hyperglycemia: the metabolic syndrome component that aggravates erectile dysfunction in Mexican patients

Hiperglucemia: el componente del síndrome metabólico que agrava la disfunción eréctil en pacientes mexicanos

Alan Espinosa-Marrón,1 Christian Aníbal Quiñones-Capistrán,1 Aquiles Rubio-Blancas,1 María del Pilar Milke-García,1 Ricardo Alonso Castillejos-Molina.1*

Abstract

Objectives: To analyze the relationship between erectile dysfunction and metabolic syndrome in a group of Mexican patients, study the influence of other morbidity factors on erectile dysfunction, and define the specific metabolic syndrome components most associated with erectile dysfunction severity.

Materials and methods: A descriptive, cross-sectional study was conducted on a group of 86 adult Mexican patients previously diagnosed with erectile dysfunction. Participants were classified as presenting with or not presenting with metabolic syndrome. Anthropometric, biochemical, and clinical parameters were determined and erectile dysfunction severity, alcohol or tobacco consumption, and depressive behavior were identified through validated questionnaires. The results were compared between the two groups.

Results: The anthropometric measures, laboratory values, and clinical characteristics were significantly different between the two groups. More patients with severe and moderate erectile dysfunction were identified in the group with metabolic syndrome. Of the metabolic syndrome components, glycated hemoglobin >5.7% and fasting glucose >110 mg/dl were significantly associated with the development of erectile dysfunction.

Limitations: The size of our study sample was a limitation, as was the observational and cross-sectional study design.

Originality: Our study results suggest that metabolic syndrome contributed to the progression of erectile dysfunction in the Mexican sample analyzed, with hyperglycemia being the most strongly associated factor.

Conclusions: Metabolic syndrome components were shown to aggravate erectile dysfunction, particularly the lack of glycemic control. The inclusion of fasting glucose and glycated hemoglobin as complementary biochemical screening in patients with erectile dysfunction should be assessed.

Keywords: Erectile dysfunction, Metabolic syndrome, Risk factors, Hyperglycemia.

Correspondencia: *Ricardo Alonso Castillejos-Molina. Dirección: Vasco de Quiroga 15, Sección XVI, Tlalpan, 14000, Ciudad de México, México. Correo electrónico: rcastillejos@hotmail.com Teléfono: (00) (52) 55 54 87 09 00 ext. 2260

1 Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Secretaría de Salud, Ciudad de México, México.

Recepción: 26 noviembre de 2019
Aceptación: 30 de diciembre de 2019
Resumen

Objetivos: analizar la relación entre la Disfunción eréctil y el Síndrome metabólico en un grupo de pacientes mexicanos, estudiar la influencia de otros factores de morbilidad en la Disfunción eréctil y definir los componentes específicos de Síndrome metabólico más asociados con la severidad de la Disfunción eréctil.

Métodos: se realizó un estudio descriptivo y transversal en 86 pacientes mexicanos adultos con Disfunción eréctil. Los participantes fueron clasificados con o sin Síndrome metabólico. La gravedad de la Disfunción eréctil, el consumo de alcohol o tabaco, y el comportamiento depresivo se identificaron a través cuestionarios validados y se compararon entre ambos grupos, así como parámetros antropométricos, bioquímicos y clínicos de interés.

Resultados: los valores antropométricos y de laboratorio, y características clínicas fueron significativamente diferentes entre los grupos. Se identificaron más pacientes afectados por Disfunción eréctil severa y moderada en el grupo con Síndrome metabólico. Entre los componentes del Síndrome metabólico, la hemoglobina glicosilada >5.7% y la glucosa en ayunas >110 mg/dl se asociaron significativamente con el desarrollo de Disfunción eréctil.

Limitaciones: el tamaño de muestra y la naturaleza transversal del diseño.

Originalidad: nuestro estudio proporciona evidencia que sugiere que el Síndrome metabólico contribuye a la progresión de la Disfunción eréctil en esta muestra de mexicanos, siendo la hiper-glucemia el factor más asociado.

Conclusiones: los componentes de Síndrome metabólico agravan la Disfunción eréctil, particularly el descontrol glucémico. Resulta relevante la inclusión de glucosa en ayunas y hemoglobina glicosilada a modo de análisis complementario en pacientes con Disfunción eréctil.

Palabras clave:
Disfunción eréctil;
Síndrome metabólico,
Factores de riesgo,
Hiperglucemia.

Introduction

Metabolic syndrome refers to a set of multifactorial alterations that increase the risk of developing type 2 diabetes mellitus and cardiovascular disease. Different international institutions have proposed diagnostic criteria. However, the Adult Panel Treatment III incorporated standardized key concepts, thus those criteria are some of the most frequently used in clinical practice for the diagnosis of metabolic syndrome: (i) blood pressure (≥130/≥85
mmHg), (ii) high-density lipoprotein cholesterol (HDL-C < 40 mg/dL), (iii) triglycerides (≥150 mg/dL), (iv) waist circumference (WC > 102 cm), and (v) fasting glucose (≥100 mg/dL). A positive diagnosis is made when three of those five criteria are present.\(^\text{(2)}\) Metabolic syndrome affects up to 30% of the population in developed countries and its incidence is on the rise.\(^\text{(3)}\) Prevalence in Mexican men varies from 45.3 to 46.4%.\(^\text{(4,5)}\)

Erectile dysfunction refers to the inability to achieve an erection as part of the multifaceted process of male sexual function. Erectile dysfunction is common among men over 50 years of age.\(^\text{(6)}\) Etiological factors include anatomic, vascular, psychological, neurological, and hormonal disorders.\(^\text{(7)}\) A total of 51.1% of Mexican men between 40 and 60 years of age are estimated to have changes in erectile function, 59.8% of whom are diagnosed with overt erectile dysfunction.\(^\text{6}\) Furthermore, projections have established that the worldwide population presenting with erectile dysfunction will reach 322 million cases by 2025.\(^\text{(6)}\)

The global prevalence of metabolic syndrome in subjects with erectile dysfunction varies between 29.4 and 79%.\(^\text{(8,9)}\) Several studies have found a close association between the two alterations,\(^\text{(3,8,9)}\) given that mechanisms underlying metabolic syndrome compromise the blood flow to the penis in numerous ways.\(^\text{(7)}\) Specifically, an association between erectile dysfunction and hypertension,\(^\text{(10)}\) type 2 diabetes mellitus,\(^\text{(11)}\) cardiovascular disease and dyslipidemia,\(^\text{(12)}\) and obesity and central adiposity has been described.\(^\text{(13)}\) Recent studies performed on a Mexican population have confirmed that the lack of glycemic control in patients with type 2 diabetes mellitus increases the risk of developing erectile dysfunction.\(^\text{(14)}\)

Despite the publication of many studies on the relation of the different components of metabolic syndrome to erectile dysfunction,\(^\text{(3,5,15)}\) the topic has not been thoroughly explored in the Mexican population, nor have the specific components of that syndrome been emphasized or identified as the most commonly associated with erectile dysfunction, its progression, and its severity. Our main objective was to analyze the relationship between metabolic syndrome and erectile dysfunction in a group of Mexican patients. Our secondary aims were to study the influence of other morbidity factors on erectile dysfunction and to define the specific metabolic syndrome components most strongly associated with erectile dysfunction severity and progression.

**Materials and Methods**

**Design**

An observational, cross-sectional study was conducted on a group of men (30-60 years of age) that were regularly seen at the Urology outpatient service of the Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán” between 2014 and 2017. The study was approved by the local Ethics Committee (approval number URO-844-13/13-1), according to national and international regulations for human studies and the 1964 Declaration of Helsinki. Individual written statements of informed consent were obtained from all participants included in the study.
Participants and settings

Patients were recruited through a printed announcement at the Urology Department. A total of 126 patients previously diagnosed with erectile dysfunction were identified. Inclusion criteria were individuals with or without type 2 diabetes mellitus (<10 years of evolution), controlled dyslipidemia (triglycerides ≤ 300 mg/dl, low-density lipoprotein cholesterol ≤200 mg/dL, with or without pharmacological treatment), controlled systemic blood pressure (<140/90 mmHg only using one antihypertensive drug) and overweight or obesity (body mass index ≥ 25 or 30 kg/m2, respectively). Exclusion criteria were uncontrolled glycemia (glycated hemoglobin ≥ 8%), uncontrolled hypertension (using two or more antihypertensive drugs, without reaching treatment goals), pharmacologic treatment for erectile dysfunction, prostate surgery, neuropathy, major depressive disorder (Beck Depression Inventory score >25), hormonal replacement therapy, pelvic radiotherapy, chronic kidney disease (glomerular filtration rate < 60 ml/min, according to the CKD-EPI formula), uncontrolled dyslipidemia (triglycerides ≥ 300 mg/dl or low-density lipoprotein cholesterol ≥200 mg/dL), possible or diagnosed hypogonadism, hypothyroidism, liver cirrhosis, alcoholism (Alcohol Use Disorder Identification Test score >8), acute myocardial infarction within the last 6 months, anatomical deformity of the sexual organs, high performance athletes, or incomplete data. A final total of 86 patients were included in the study.

Clinical and nutritional evaluation

The simplified International Index of Erectile Function-5 questionnaire was applied to identify erectile dysfunction severity (mild, mild-moderate, moderate, and severe). Smoking and alcohol consumption were assessed through the Fagerström test and the Alcohol Use Disorders Identification Test, respectively. Depressive behavior that could indirectly modify erectile function was identified through the Beck Depression Inventory. Metabolic syndrome was diagnosed according to the Adult Panel Treatment III criteria (frequently used in patients with erectile dysfunction). Furthermore, anthropometric measurements (weight, height, neck circumference, and waist circumference) were carried out according to the International Society for the Advancement of Kinanthropometry guidelines. Blood pressure and the following chemical biomarker values were retrieved from the hospital medical records: fasting glucose, glycated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, serum testosterone, and estradiol concentrations.

Statistical analysis

Normality tests were performed for the continuous variables. Means for independent samples were compared through the Student’s t-test. A logistic regression analysis was carried out to identify the risk factors for erectile dysfunction. Beta coefficients with odds ratio (OR) and 95% confidence intervals (95% CI) were determined. A p <0.05 value was considered significant. The statistical analysis was performed using the IBM SPSS version 21 Statistics® Software.
Results

One hundred and twenty-six patients were initially considered. We excluded 40 candidates and the remaining 86 participants were classified into two groups, according to a positive (70.9%) or negative metabolic syndrome diagnosis, as depicted in figure 1. Clinical characteristics are compared in table 1. Significant differences in the anthropometric parameters (weight, body mass index, neck circumference, and waist circumference), laboratory values (triglycerides, total cholesterol, glucose, and glycated hemoglobin), clinical characteristics (blood pressure), and the Beck Depression Inventory score were found. However, no differences were detected in the overall International Index of Erectile Function-5 score (13.34 vs 13.76, respectively; p = 0.707) or the testosterone or estradiol values between the participants that presented with metabolic syndrome and those that did not.

Figure 1. Classification of the study patients based on metabolic syndrome diagnosis, according to the Adult Treatment Panel III.
Table 1. Comparison of clinical characteristics in patients presenting with erectile dysfunction, with or without metabolic syndrome.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Yes (n=61)</th>
<th>No (n=25)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52.6 ± 9.6</td>
<td>50.4 ± 8.1</td>
<td>0.28</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>86.7 ± 13.1</td>
<td>74.3 ± 12.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.3 ± 4.1</td>
<td>26.4 ± 4.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>105.6 ± 10.4</td>
<td>95.0 ± 11.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NC (cm)</td>
<td>42.5 ± 3.1</td>
<td>39.8 ± 3.1</td>
<td>0.001</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>190.4 ± 88.9</td>
<td>118.8 ± 49.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>39.6 ± 8.8</td>
<td>48.6 ± 8.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>121.2 ± 46.4</td>
<td>98.5 ± 43.3</td>
<td>0.036</td>
</tr>
<tr>
<td>Hb1Ac (%)</td>
<td>6.4 ± 1.4</td>
<td>5.4 ± 0.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total testosterone (ng/dL)</td>
<td>422.4 ± 148.3</td>
<td>448.6 ± 128.3</td>
<td>0.54</td>
</tr>
<tr>
<td>Estradiol (pg/mL)</td>
<td>32.4 ± 22.1</td>
<td>26.8 ± 14.2</td>
<td>0.36</td>
</tr>
<tr>
<td>SP (mmHg)</td>
<td>125.5 ± 12.2</td>
<td>119.5 ± 10.9</td>
<td>0.032</td>
</tr>
<tr>
<td>DP (mmHg)</td>
<td>81.8 ± 8.8</td>
<td>77.4 ± 7.5</td>
<td>0.024</td>
</tr>
<tr>
<td>IIEF-5 (total score)</td>
<td>13.3 ± 4.5</td>
<td>13.7 ± 4.6</td>
<td>0.707</td>
</tr>
<tr>
<td>BDI (total score)</td>
<td>9.8 ± 7.8</td>
<td>5.5 ± 4.3</td>
<td>0.002</td>
</tr>
<tr>
<td>AUDIT (total score)</td>
<td>3.2 ± 4.8</td>
<td>1.8 ± 2.5</td>
<td>0.091</td>
</tr>
<tr>
<td>Fagerström test (total score)</td>
<td>0.1 ± 0.7</td>
<td>0 ± 0</td>
<td>0.055</td>
</tr>
</tbody>
</table>

* According to the Adult Panel Treatment III diagnostic criteria. International System of Units conversions: 1 mg/dL of HDL-C= 0.26 mmol/L; 1 mg/dL of TG= is 0.01 mmol/L; 1 mg/dL of glucose= 0.06 mmol/L.

Abbreviations: BMI= body mass index; WC= waist circumference; NC= neck circumference; TG= triglycerides; HDL-C= high-density lipoprotein cholesterol; HbA1c= glycated hemoglobin; SP= systolic pressure; DP= diastolic pressure; IIEF-5= International Index of Erectile Function-5; BDI= Beck’s Depression Inventory; AUDIT= Alcohol Use Disorders Identification Test.

Erectile dysfunction severity was classified according to cut-off points into mild, mild-moderate, moderate, and severe, and then further analyzed, considering the presence of metabolic syndrome. More patients in the metabolic syndrome group were affected by severe (n=6, 66.7%) and moderate (n=13, 72.2%) erectile dysfunction. Erectile dysfunction was more severe in the patients with glycated hemoglobin > 5.7%, when compared with the patients that had normal glucose metabolism (14.6 vs 12.2, p = 0.014, respectively) (Table 2). The linear regression analysis (Table 3) identified both glycated hemoglobin >5.7% and fasting glucose >110 mg/dL as significant risk factors for the development of erectile dysfunction (OR= 48.76, 95% CI= 3.6 – 659.26, p= 0.004; OR= 15.62, 95% CI= 1.12 – 250, p = 0.04, respectively).
Table 2. Metabolic alterations associated with metabolic syndrome and the IIEF-5 score.

<table>
<thead>
<tr>
<th>Metabolic alteration</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>mean ± SD</td>
</tr>
<tr>
<td>WC &gt; 102 cm</td>
<td>42</td>
<td>13.8 ± 4.4</td>
</tr>
<tr>
<td>TG ≥ 150 mg/dL</td>
<td>45</td>
<td>13.4 ± 3.6</td>
</tr>
<tr>
<td>AP ≥ 130/85 mmHg</td>
<td>15</td>
<td>14.0 ± 4.8</td>
</tr>
<tr>
<td>HDL-C &lt; 40 mg/dL</td>
<td>44</td>
<td>13.0 ± 4.3</td>
</tr>
<tr>
<td>Fasting glucose &gt; 110 mg/dL</td>
<td>26</td>
<td>13.5 ± 4.3</td>
</tr>
<tr>
<td>HbA1c &gt; 5.7%</td>
<td>41</td>
<td>12.2 ± 4.4</td>
</tr>
</tbody>
</table>

International System of Units conversions: 1 mg/dL of HDL-C= 0.26 mmol/L; 1mg/dL of TG= 0.01 mmol/L; 1 mg/dL of glucose= 0.06 mmol/L.

Abbreviations: IIEF-5= International Index of Erectile Function-5; WC= waist circumference; TG= triglycerides; BP= blood pressure; HDL-C= high-density lipoprotein cholesterol; HbA1c= glycated hemoglobin; SD= standard deviation.

Table 3. Risk factors associated with erectile dysfunction.a

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Beta Coefficient</th>
<th>OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic syndrome b</td>
<td>-0.087</td>
<td>0.42 (0.01–10.58)</td>
<td>0.594</td>
</tr>
<tr>
<td>Fagerström test</td>
<td>-0.034</td>
<td>0.55 (0.01–26.54)</td>
<td>0.761</td>
</tr>
<tr>
<td>AUDIT</td>
<td>0.099</td>
<td>11.19 (0.04–2900.38)</td>
<td>0.389</td>
</tr>
<tr>
<td>BDI</td>
<td>0.145</td>
<td>4.06 (0.38–43.22)</td>
<td>0.241</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.021</td>
<td>1.27 (0.07–21.85)</td>
<td>0.863</td>
</tr>
<tr>
<td>Hb1Ac &gt; 5.7%</td>
<td>0.432</td>
<td>48.76 (3.6–659.26)</td>
<td>0.004</td>
</tr>
<tr>
<td>Glucose &gt; 110 mg/dL</td>
<td>-0.28</td>
<td>15.62 (1.12–250)</td>
<td>0.04</td>
</tr>
<tr>
<td>HDL-C &lt; 40 mg/dL</td>
<td>0.1</td>
<td>2.46 (0.22–26.84)</td>
<td>0.455</td>
</tr>
<tr>
<td>Triglycerides ≥ 150 mg/dL</td>
<td>0.04</td>
<td>1.43 (0.14–14.01)</td>
<td>0.751</td>
</tr>
<tr>
<td>WC &gt; 102 cm</td>
<td>0.08</td>
<td>2.06 (0.1–39)</td>
<td>0.626</td>
</tr>
<tr>
<td>BMI ≥ 30 kg/m²</td>
<td>-0.409</td>
<td>0.02 (0.0002–1.93)</td>
<td>0.094</td>
</tr>
<tr>
<td>25 ≤ BMI &lt; 30 kg/m²</td>
<td>-0.106</td>
<td>0.38 (0.01–10.37)</td>
<td>0.566</td>
</tr>
<tr>
<td>Testosterone &lt; 350 mg/dL</td>
<td>-0.268</td>
<td>1.3 (0.05–11.66)</td>
<td>0.846</td>
</tr>
</tbody>
</table>

a Linear regression analysis.
b Diagnosis according to the Adult Panel Treatment III criteria.

International System of Units conversions: 1 mg/dL of HDL-C= 0.26 mmol/L; 1mg/dL of TG= is 0.01 mmol/L; 1 mg/dL of glucose= 0.06 mmol/L.

Abbreviations: Metabolic syndrome = Metabolic Syndrome, AUDIT= Alcohol Use Disorders Identification Test; BDI= Beck’s Depression Inventory; HbA1c= glycated hemoglobin; HDL-C= high-density lipoprotein cholesterol; WC= waist circumference; BMI= body mass index, OR= Odds ratio, 95% CI= 95% confidence interval.
Discussion

Our study provides relevant evidence suggesting that erectile dysfunction pathogenesis is exacerbated by metabolic syndrome in a Mexican population, especially by uncontrolled glycemia. Poor eating habits have been reported in different Mexican surveys. The results of the latest national health survey Encuesta Nacional de Salud y Nutrición (ensanut), showed that the combined prevalence of overweight/obesity reached 72.5% in adults (<20 years of age). Overweight/obese patients usually present with glycemic dysregulation secondary to elevated concentrations of serum-free fatty acids (induced by apoptosis of the pancreatic β-cells) and leptin and TNF-α (both of which restrict insulin secretion), subsequently reducing insulin secretory capacity.

Méndez-Hernández et al., reported that individuals classified as having undesirable eating habits have an 8.8 (95% CI = 3.1-25) and 11.1 (95% CI = 3.4-36.1) higher risk of developing metabolic syndrome (considering the NCEP-ATP III and International Diabetes Federation criteria, respectively) and an 11.2 (95% CI = 3.9-31.5) higher probability of presenting with insulin resistance, when compared with individuals that have healthier eating habits. Consequently, subjects with undesirable eating habits are also predisposed to develop erectile dysfunction, which could explain the large prevalence of erectile dysfunction found in our Mexican patients.

Furthermore, our results agree with those published by Chao et al., who found a significant association between anthropometric parameters, such as central obesity (for the Asian population, waist circumference ≥ 90 cm), and erectile dysfunction (p = 0.007). Other studies on different populations have shown that particular relationship. However, in contrast to our results, there is evidence showing a significant difference in the International Index of Erectile Function-5 score between men that do not present with metabolic syndrome and those that present with the syndrome (21.76 ± 3.59 vs 18.26 ± 5.08 respectively, p<0.001), possibly indicating that erectile dysfunction prevalence increases when a patient has more components of metabolic syndrome.

Regarding arterial hypertension, the authors of a multicenter cross-sectional study on 512 hypertensive patients that answered the International Index of Erectile Function-5 questionnaire, reported a prevalence of erectile dysfunction of 46.5%, like that found in our study. However, evidence on the association between depression, metabolic syndrome, and erectile dysfunction described in the medical literature is not conclusive. In a prospective study on patients with metabolic syndrome (n=5,232), only central obesity, high triglyceride concentration, and low high-density lipoprotein cholesterol concentration predicted depression symptoms. Our results demonstrated a trend toward the development of depression in patients with metabolic syndrome diagnosed through the Beck Depression Inventory.

Our biochemical results matched those reported in a systematic review and meta-analysis by Besiroglu et al., in which there was a positive association between erectile dysfunction and hyperlipidemia. In a prospective study on a cohort of men, hypercholesterolemia was found to be a long-term erectile dysfunction predictor. Moreover, data from experimental models have demonstrated that the atherosclerotic process caused by hypercholesterolemia affects the
corpus cavernosum and that the reduction of serum cholesterol normalizes cavernosal relaxation, suggesting that the corpus cavernosum smooth muscle dysfunction caused by hypercholesterolemia is reversible. In that context, a prospective clinical trial evaluated the impact of cardiovascular risk factors on erectile function. Those authors concluded that age, body mass index, total cholesterol, and triglyceride concentrations were significantly associated with erectile dysfunction.

With respect to the lack of glycemic control, Maseroli et al., reported a higher prevalence of hyperglycemia (fasting glucose >100 mg/dl) in patients with sexual dysfunction than in patients not presenting with the disorder (44.5 vs 33.3%, p< 0.05). Specifically, those authors observed a direct relation between a higher serum glucose concentration and the development of erectile dysfunction. Furthermore, Pohjantähti-Maaroos et al., analyzed 57 subjects with metabolic syndrome, comparing them with 48 physically active individuals, and found there were more cases of erectile dysfunction in the metabolic syndrome group. In addition, the patients with metabolic syndrome and erectile dysfunction had a higher mean serum glucose concentration than the patients with metabolic syndrome that did not present with erectile dysfunction (6.99 ± 2 mmol/l vs 6.54 ± 1 mmol/l, respectively) (p< 0.001). Xu et al., recruited patients with type 2 diabetes mellitus and evaluated erectile dysfunction (through the International Index of Erectile Function-5) and concluded that the risk for erectile dysfunction was greater in patients with poor glycemic control. An observational study on a Mexican population, in which glycated hemoglobin concentrations were associated with the overall score on the International Index of Erectile Function-5 questionnaire, produced an odds ratio of 6.92.

In that set of patients, the prevalence of erectile dysfunction was 72% and the lack of glycemic control was observed in 80.9% of the patients. Similar results were found in our study, concluding that glycated hemoglobin >5.7% and/or fasting glucose >110 mg/dl may directly influence the severity of erectile dysfunction in patients with metabolic syndrome.

Although it is well known that erectile dysfunction is potentially caused by testosterone deficiency, hypogonadism, and age, and in addition, the long-term benefit of testosterone replacement has been addressed, our results did not show a relation between testosterone concentrations below 346 ng/dl (12 nmol/l) and the development of erectile dysfunction in patients with metabolic syndrome, nor did they corroborate an etiological association between patient age and the development of erectile dysfunction. Nonetheless, hyperglycemia promotes alterations in the concentrations of nitric oxide, cyclic guanosine monophosphate (cGMP), and free radicals, as well as in endothelin B biosynthesis, all possible direct causes of erectile dysfunction. Consequently, the etiology of erectile dysfunction is closely related to different factors specifically associated with glycemic dysregulation, in that particular group of patients. However, both adipose tissue-derived hormones (which are also associated with insulin resistance) and vascular disease compromise blood flow to the penis and are presumably caused by nitric oxide synthase inhibition. Therefore, to have an overall pathophysiological understanding of erectile dysfunction, adipokines should be considered in patients that present with erectile dysfunction and metabolic syndrome.
Our study provides evidence on metabolic syndrome as a risk factor for the development and progression of erectile dysfunction that can be extrapolated to other Latin American populations. In addition to the fact that our findings partially coincide with the existing evidence,\(^{(9,15)}\) we reinforce the hypothesis that hyperglycemia promotes the development of erectile dysfunction. Standards for the prevention and treatment of erectile function that focus on metabolic and glycemic control are fundamental for improving the condition. However, limitations of our study were its observational and cross-sectional design and the size of the sample, possibly reducing the statistical reliability of our analysis. In the context of small sample size, employing logistic regression as an analytical tool could overestimate the effect, yielding large confidence intervals and possibly biased odds ratios.\(^{(31)}\) Nevertheless, our adequate and well-designed sampling strategy rectified the performance of the estimates. That probable source of bias in a single study might not be relevant in the interpretation of the results, given that said misrepresentation usually occurs when small studies with systematically underestimated effect sizes are pooled together (i.e., meta-analysis).\(^{(31)}\) Thus, those limitations are not major concerns regarding the clinical interpretation of our exploratory design, which may be helpful in the development of etiological hypotheses for future larger longitudinal studies.

**Conclusions**

Metabolic syndrome components were directly associated with the severity of erectile dysfunction, particularly hyperglycemia, manifested by glycated hemoglobin >5.7% and fasting glucose >110 mg/dL. Those results agree with other previously published findings. However, our study provides a specific description of the influence of each metabolic syndrome component on the severity of erectile dysfunction. Therefore, it is necessary to produce population-based guidelines and recommendations to develop a multidisciplinary treatment for erectile dysfunction that addresses the importance of metabolic syndrome prevention by promoting an adequate lifestyle for Latin American men. The present study contributes to that goal by strongly suggesting the inclusion of basal glucose and/or HbA1c as complementary biochemical screening for erectile dysfunction.

**References**


